Mild Cognitive Impairment
1,232
186
262
615
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
182 trials with published results (15%)
Research Maturity
615 completed trials (50% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.1%
51 terminated out of 1232 trials
92.3%
+5.8% vs benchmark
4%
52 trials in Phase 3/4
30%
182 of 615 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 615 completed trials
Clinical Trials (1232)
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Impact of Intensive Computerized Cognitive Training
A Novel Multi-Modal Approach to Promote Functional Outcomes in Cognitively Frail Older Adults
Alzheimer's Disease Neuroimaging Initiative 4
Choose Myself (Before) Losing Myself
Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
Memory Support System Feasibility Study
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Virtual Outreach and Individualized Coaching Extension
Brain Heath Service for Prevention of AD
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Music for Pain and Dementia
Improving Neurological Health With Acetylcholine Via Neuroplasticity-based Computerized Exercise in Mild Cognitive Impairment
Microbiome in Aging of Gut and Brain
SYNERGIC-2 Trial (SYNchronizing, Exercises and Remedies to GaIn Cognition@Home)
Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants